{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001177648","name":"ENANTA PHARMACEUTICALS INC","summary":"Enanta Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs for virology and immunology. It discovered glecaprevir, commercialized by AbbVie as MAVYRET/MAVIRET for HCV treatment. Enanta has two clinical RSV candidates (zelicapavir, EDP-323) and preclinical immunology programs targeting KIT and STAT6 for conditions including chronic spontaneous urticaria and atopic dermatitis, earning royalties from AbbVie's HCV sales.","people":[],"products":[{"name":"Glecaprevir (MAVYRET/MAVIRET)","type":"platform","description":"HCV protease inhibitor co-formulated with pibrentasvir; pan-genotypic, once-daily treatment for chronic and acute HCV, commercialized by AbbVie."},{"name":"Zelicapavir (EDP-938)","type":"platform","description":"Oral, once-daily RSV N-protein inhibitor in Phase 2 studies for high-risk adults and pediatric patients; has FDA Fast Track designation."},{"name":"EDP-323","type":"platform","description":"Oral RSV L-protein inhibitor with sub-nanomolar potency; completed Phase 2a challenge study; has FDA Fast Track designation."},{"name":"EDP-978","type":"platform","description":"Preclinical oral KIT inhibitor targeting mast cell-driven diseases such as CSU; IND filing expected Q1 2026."},{"name":"EPS-3903","type":"platform","description":"Preclinical oral STAT6 inhibitor targeting IL-4/IL-13 signaling for atopic dermatitis and other type 2 immune diseases; IND filing targeted H2 2026."}],"partnerships":[{"partner_name":"AbbVie","partnership_type":"licensing","description":"Collaborative Development and License Agreement; AbbVie developed and commercializes glecaprevir-based HCV regimens; Enanta receives royalties on MAVYRET/MAVIRET net sales.","start_date":null},{"partner_name":"OMERS","partnership_type":"strategic","description":"In April 2023, Enanta sold 54.5% of future MAVYRET/MAVIRET royalties to an OMERS affiliate for $200 million, subject to a 1.42x cap.","start_date":null}],"affiliations":[],"origin":{"leaf":"ff07b6341db67f7dcf2c560783317307fb3eb083da53f55f36bbeff631a4d3bf","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"4505820eea6dfcd46042af66496965e9fd8fef70dbd0fee0dbdbea84bc5344bd","parent":"37066c065dc4043a5aca68043238e25b825ac16357c311b840601f6f254aad30","source":"0001193125-25-288121","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":129,"hourly_limit":500,"remaining":371,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}